Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LONP1 | P36776 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.43 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.43 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.43 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.43 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.43 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.43 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609384 | 0.87 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1ALDH1A1NFKB1RAB9A | |
| SCHEMBL606058 | 0.86 | TRPV1 (0.51) | SMN1; SMN2NPC1RAB9APLGTRPV1 | |
| SCHEMBL3169902 | 0.84 | LONP1 (0.66) | NFKB1NFKB2RELALONP1PSMB11 | |
| SCHEMBL2935514 | 0.83 | POLB (0.48) | SMN1; SMN2NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL3173663 | 0.83 | CTSS (0.47) | SMN1; SMN2NPC1RAB9ATRPV1CTSL | |
| SCHEMBL2930963 | 0.80 | DHODH (0.47) | SMN1; SMN2NPC1ALDH1A1NFKB1RAB9A | |
| SCHEMBL607104 | 0.80 | LMNA (0.49) | LMNAHPGD | |
| SCHEMBL607137 | 0.79 | CA2 (0.54) | SMN1; SMN2KDM4E | |
| SCHEMBL3168547 | 0.79 | CTSS (0.44) | SMN1; SMN2NPC1RAB9APLGCTSL | |
| SCHEMBL609415 | 0.78 | L3MBTL1 (0.49) | SMN1; SMN2NPC1RAB9AHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | SMN1; SMN2 1107/4885NPC1 2178/4885ALDH1A1 3935/4885 |
| US-20120041196-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | SMN1; SMN2 1107/4885NPC1 2178/4885ALDH1A1 3935/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | SMN1; SMN2 1107/4885NPC1 2178/4885ALDH1A1 3935/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | SMN1; SMN2 1107/4885NPC1 2178/4885ALDH1A1 3935/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | SMN1; SMN2 1107/4885NPC1 2178/4885ALDH1A1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.